Synergistic hepatoprotective effect of combined administration of Lachnum polysaccharide with silymarin
Related Experiment Video
Updated: Nov 3, 2025

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
Ziyang Ye1, Xinmiao Zhang1, Qianli Huang1
1School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, China.
Abstract:
In recent years, combination therapy has gradually become one of the hot spots. As a new therapy strategy, we investigated the combination treatment of polysaccharide from Lachnum sp. (LEP-2b) with silymarin and compared the effects with mono-therapy. In this study, combining high-dose LEP-2b with silymarin (CH) significantly reduced serum biochemistry indexes (ALT, AST, AKP, LDH), hepatic inflammation (TNF-α, IL-6 and IL-1β) and improved the antioxidant status (SOD, CAT, GSH-Px, GSH, MDA and T-AOC), in which its effect on TNF-α was very significant (P < 0.001). Therefore, the expressions of related proteins in the JNK/p38 signaling pathway associated with TNF-α were examined. The result showed that CH treatment markedly increased the expression of p-p38 and inhibited the JNK phosphorylation. TUNEL staining, immunohistochemical staining and western blot assays demonstrated that the hepatoprotective effect of CH treatment was probably related with inhibiting hepatocyte apoptosis. In summary, combination of high dose LEP-2b with silymarin would be a more effective method to protect liver injury than mono-therapy.
More Related Videos
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

